GlassScriptPhysician profile
Steven H Levy
NPI 1497849426
$4,407.63
in general payments reported to CMS, 2019-2025
27 companies · $827 in 2025
The $827 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $149 · 2021: $419 · 2022: $470 · 2023: $1,005 · 2024: $768 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.42 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $417.02 | 2019-2025 | Rexulti, Abilify Mycite |
| Axsome Therapeutics, INC. | $391.77 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $337.80 | 2019-2025 | Ingrezza |
| Corium, LLC | $301.78 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $291.65 | 2019-2025 | Trintellix |
| Lundbeck LLC | $287.15 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.40 | 2022-2025 | Caplyta |
| Neuronetics, INC. | $185.37 | 2019 | |
| Allergan, INC. | $127.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $127.54 | 2021-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $93.78 | 2019-2020 | |
| Alkermes, INC. | $93.42 | 2022-2023 | Aristada, Lybalvi |
| Bausch Health US, LLC | $92.94 | 2019-2023 | Aplenzin |
| Vanda Pharmaceuticals INC. | $85.88 | 2019-2025 | Fanapt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $45.09 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $33.77 | 2022-2023 | Belsomra |
| Vertical Pharmaceuticals, LLC | $30.28 | 2019-2020 | |
| Harmony Biosciences LLC | $29.09 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.59 | 2025 | Austedo Xr |
| Neos Therapeutics, LP | $18.85 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $18.78 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.19 | 2019 | |
| Sage Therapeutics, LLC | $18.12 | 2024 | |
| Adlon Therapeutics L.P. | $16.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.65 | 2022 | |
| Eisai INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.